Todo lo que quisiste saber sobre el cáncer y nunca supiste a quién preguntar

Iker Badiola (Ondarroa, Bizkaia, 1978) is a professor and researcher at the University of the Basque Country / Euskal Herriko Unibertsitatea (UPV/EHU), Faculty of Medicine and Nursing. During his professional career he has been dedicated to researching the cellular and molecular basis of liver metastasis. He is the author of about twenty scientific articles and a patent, has directed three doctoral theses, and has written four books on histology, aimed at health professionals. He has spent time at the University of Copenhagen and the University of Toronto. He is a founding partner of the biotechnology company INNOPROT SL. In 2006 he was awarded the prize for the best young researcher at the 13th ISCHS Congress held in Niigata (Japan). In 2019 he received the Ernesto Viéitez prize, awarded by the Royal Academy of Galician Sciences, together with a team of researchers from different disciplines, for developing an antitumor therapy.

Arkaitz Carracedo, Biokimikan eta Biologia Molekularrean doktorea Madrilgo Unibertsitate Konplutentsean (2006). MSKCCn (NY) eta BIDMCn (Boston, AEB) 4 urtez doktoratu ondoren, CIC bioGUNEn ezarri zuen bere ikerketa-lerroa 2010. urtearen amaieran, in vitro eta in vivo minbizi-zelulen ezaugarri biologiko bakarrak aztertzeko helburu nagusiarekin, metabolismo zelularraren asaldurak azpimarratuz. 2011tik Ikerbasque ikerketa-irakaslea da, eta 2012tik, gainera, Euskal Herriko Unibertsitateko irakasle elkartua. Minbiziaren metabolismoaren esparruan eragina izan du 108 argitalpen eta berrikuspen zientifikorekin eta nazioarteko aintzatespenerako kongresuen antolaketarekin. Bere ospea hainbat sari eta aintzatespenetan islatzen da, baita estatuko eta nazioarteko eragile garrantzitsuenek (AECC, La Caixa, ERC) bere ikerketa finantzatzea ere.

Dr. Isabela Díaz de Corcuera has a degree in Medicine and Surgery from the UPV/EHU, and is a specialist in Medical Oncology. She currently works in the Oncology Service of the Galdakao Hospital. In her long professional career she has worked at Cruces Hospital, at the Clinical Observer Hospital Royal Marsden, (England) Breast/Lung Cancer Department, Medical Oncology, at the Catalan Institute of Oncology, L'Hospitalet (Barcelona). (Barcelona), in the service of Medical Oncology at the Hospital Vall d'Hebron (Barcelona). Vall d'Hebron (Barcelona), Head/Neck and Gynecologic Tumors Unit, Clinical Observer at Langone Medical Center (NYU Hospital Cancer Institute, New York), Hereditary Cancer Counseling Unit, Hospital Vall d'Hebron (Barcelona). She is the author of several scientific articles and received her PhD from the UPV/EHU with a thesis on anti-EGFR therapy in head and neck tumors.

La Dra. Cristina Eguizabal, es licenciada en Ciencias Biológicas y Bioquímicas por la Universidad de Navarra y doctora en Biología Celular y Embriología Experimental por la UPV. Ha realizado estancias como, en el laboratorio del Prof. Massimo de Felici en la Universidad de Tor Vergata, Roma y se incorporó al grupo de Prof. Anne McLaren-Azim Surani en el Gurdon Institute-Universidad de Cambridge (UK). Posteriormente, se incorporó en el CMRB liderado por Juan Carlos Izpisua, como investigadora senior. Posee un amplio conocimiento en células madre embrionarias y células madre pluripotentes inducidas (iPS) de diversos orígenes y diferenciación celular a diversos tipos celulares. La Dra. Eguizabal es Past-Coordinadora de “SIG- Stem Cells of ESHRE”. Profesora del Máster de Biología de la Reproducción y TRA (UAB-Dexeus). La Dra. Eguizabal desde 2013 es la responsable de la Unidad de Investigacion del CVTTH y Jefa de Grupo de Terapia Celular, Celulas Madre y Tejidos del IIS Biocruces Bizkaia.

I received my PhD in Biochemistry in 2006 at the UPV/ EHU. The topic of my PhD Thesis, supervised by Dr. Ana Zubiaga, focused on the function of the RB/E2F pathway in the control of tissue function. I did a postdoc (2006-2008) at the University of Southern California (USA), in the field of liver cancer, in the group led by Dr. Shelly C. Lu. In 2008 I rejoined the Consolidated Research Group of Molecular Biology of Cancer of the UPV/ EHU and since 2017 I am Full Professor. My research activity is developed in the field of cancer, making use of cellular and animal genetic models to elucidate the role of key proteins in tumor suppression. I have participated in 30 research projects, 20 international publications, more than 20 national and international congresses and I have directed 2 PhD Theses. My teaching activity is developed in two subjects in the Degree in Biology: Genetics and Genetic Engineering and Molecular Genetic Analysis.

Gorka Larrinaga is a professor and researcher at the Faculty of Medicine and Nursing of the UPV/EHU and belongs to the Cancer Biomarkers Group at the Biocruces-Bizkaia Research Institute. He has been researching in the area of oncology for 15 years. He has participated in more than 30 research projects, has published more than 50 articles in international journals of impact and also has experience as a disseminator in the area. He is currently investigating the tumor microenvironment in urinary tract tumors and colorectal cancer.

Yurena Polo Arroyabe (1988) 2011n Biologian lizentziatu zen Bartzelonako Unibertsitate Autonomoan (UAB). Birus bektoreak eta birosomak sortzen hasi zen lehenik Amarna Therapeutics BV eta gero Mymetics BV (biak Leiden, Herbehereak). Horren ostean, bere prestakuntzarekin jarraitzea erabaki zuen eta Biologia Molekularreko eta Biomedikuntzako Masterra egin zuen Euskal Herriko Unibertsitatearen (EHU) eta Kantabriako Unibertsitatearen (Bu) artean. Banco Santander bekari esker, Inbiomeden master amaierako proiektua egin zuen, hiPSCetatik eratorritako neuronen aldaketa transkripzionalak induzitu eta ondoren detektatzeko. 2018tik aurrera, Polimerbio SL enpresan ari da lanean, mediku biodegradagarri berriak sortzen. Aldi berean, Bikaintek bekari esker doktoretza industriala egin zuen Zibio taldean. Doktorego-tesiaren ardatza ehun neurala birsortzea da, grafenoan oinarritutako ainguraketa zelularreko matrizeak erabiliz.

Maider Zabala, is co-founder and CSO of Onena Medicines. She completed her thesis at CIMA, where she developed new viral vectors to reduce the toxicity associated with immunotherapeutic treatments for the treatment of cancer. In 2007, Maider obtained the prestigious Fulbright international grant to continue her post-doctoral studies at Stanford University (California; USA). Maider continued her stay at Stanford as an instructor for a total of 11 years. Maider co-led several research projects investigating new mechanisms that confer immortality to breast cancer cells. Part of these studies, such as the identification of DSIP proteins and their role in breast cancer development, have been the basis for the creation of Onena Medicines. Maider has published numerous articles in scientific journals such as Cell, Science, Cell Stem Cell.